UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS INC., Petitioner,
$\mathbf{V}.$
SANOFI-AVENTIS DEUTSCHLAND GMBH, Patent Owner.
Case No. IPR 2018-01676

Case No. IPR2018-01676 U.S. Patent No. 8,603,044

DECLARATION OF DR. ROBIN S. GOLAND IN SUPPORT OF PATENT OWNER'S RESPONSE TO PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 8,603,044

Sanofi Exhibit 2111.001




TABLE OF CONTENTS

I.	Background and Experience	1
II.	Fees and Prior Testimony	3
III.	Materials Reviewed and Information Considered	3
IV.	Summary of Opinions	4
V.	Background on Diabetes & Treatments	5
VI.	Sanofi's Lantus® SoloSTAR® Product	6
VII.	A Long-Felt but Unmet Need Existed for an Easy-to-Use, Disposable Pen	7
VIII.	Pens Prior to SoloSTAR® did not Meet the Long-Felt Need for an Easy-to-Use, Disposable Pen	9
IX.	SoloSTAR® Met A Long-Felt but Unmet Need Existed for an Easy-to-Use, Disposable Pen	11
Mate	rials Considered	16







I, Robin S. Goland, M.D., have been retained by Sanofi-Aventis

Deutschland GmbH ("Patent Owner" or "Sanofi"), as an independent expert

witness in the above-captioned *inter partes* review ("IPR") that has been instituted.

I understand that Mylan Pharmaceuticals Inc. ("Mylan" or "Petitioner") has

requested that the U.S. Patent and Trademark Office cancel as unpatentable certain

claims of this patent.

This declaration sets forth my analyses and opinions based on my experience and the materials I have considered. As I explain below, it is my opinion that Lantus® SoloStar® satisfied a long-felt but unmet need for a long-lasting insulin or insulin glargine drug in an easy-to-use disposable pen.

I. Background and Experience

- 1. Included as Exhibit 2112 to this declaration is my current curriculum vitae. I have summarized my educational and professional background below.
- I received a Bachelor of Arts in History from Harvard University in
 After completing my undergraduate studies, I went on to obtain an M.D.
 degree from Columbia University in 1980.
- 3. After completing my internship in 1981, I undertook a residency in internal medicine at New York-Presbyterian/Columbia University from 1980-1984. I completed a fellowship in endocrinology at Columbia University College

1



of Physicians and Surgeons in 1987. I am board-certified in Internal Medicine and Endocrinology.

- 4. Since completing my residency and fellowship, I've held a number of academic positions at Columbia University College of Physicians and Surgeons, including Assistant Professor of Clinical Medicine (1987-1989), Assistant Professor of Medicine (1990-1996), Florence Irving Associate Professor of Medicine (1997-2008), Professor of Clinical Medicine (2008-present), Professor of Clinical Medicine and Clinical Pediatrics (2010-present), and J. Merrill Eastman Professor of Clinical Diabetes (2011-present).
- 5. Since 1987, I have been the Chief of the Diabetes Clinic at New York-Presbyterian Hospital/Columbia University. In 1997, I founded the Naomi Berrie Diabetes Center at Columbia University, and I have served the center as co-director ever since. The Naomi Berrie Diabetes Center serves 14,000 patients each year, approximately 40% of which have Type 1 diabetes. In addition, the Center conducts clinical research on diabetes.
- 6. During my career, I have authored or co-authored over 80 peer-reviewed articles. I am a member of the American Diabetes Association. I also served as a member of the Medical Advisory Board of the Juvenile Diabetes Foundation, New York Chapter, the Pharmacy and Therapeutics Committee of

2





Merck Health Solutions, and the Medical Advisory Board of the NY Stem Cell Foundation.

- 7. I am an experienced clinical investigator and principal investigator in diabetes trials. In 1996-1999, I received the Irving Scholar Award for Clinical Investigation from Columbia University.
 - 8. My other qualifications are set forth in my curriculum vitae.

II. Fees and Prior Testimony

- 9. In the past five years, I have testified as an expert in deposition and at trial in the *Sanofi v. Merck* litigation, Case No. 16-812-RGA, in the District of Delaware.
- 10. I am being compensated for my time at my standard rate of \$750 for each hour of service that I provide in connection with these proceedings. This compensation is not contingent upon my opinions or testimony, the outcome of these proceedings, or any issues involved in or related to this IPR.

III. Materials Reviewed and Information Considered

11. The declaration and opinions set forth herein are based on references and other documents cited in this declaration and/or identified in the list of materials at the end of this Declaration, and my personal education, professional experience, and other relevant knowledge.

3



Sanofi Exhibit 2111.005

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

